Gubra AS (HAM:PI3) Cash Payments

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:PI3 Gubra AS HAM:PI3
53 GF Score
Price €47.32
GF Value €388.86
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Gubra AS Cash Payments?

Cash Payments only applicable to companies reporting Cash Flow from Operations in direct method.

HAM:PI3
53GF Score
Gubra AS HAM:PI3
Cash Payments is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Gubra AS (HAM:PI3) Overvalued in 2026?

Based on GuruFocus' analysis, Gubra AS stock appears to be undervalued. The current stock price of €47.32 is trading 87.8% below its estimated GF Value™ of €388.86. GuruFocus considers Gubra AS to be Possible Value Trap.

Key valuation signals for HAM:PI3:

  • Cash Payments:
  • GF Value™: €388.86 vs. price of €47.32 (87.8% below fair value)
  • GF Score™: 53/100 with 3 warning signs

No single metric tells the full story. See the HAM:PI3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Gubra AS Business Description

Other Exchanges GUBRA:DenmarkPI3:Germany
Address Horsholm Kongevej 11B, Horsholm, DNK, 2970
Gubra AS is a specialized preclinical CRO and biotech company focused on peptide-based drug discovery within metabolic and fibrotic diseases. The company has two segments: Pre-clinical contract research (CRO), which derives maximum revenue and Biotech Segment. It derives maximum revenue from Pre-clinical contract research (CRO) segment. Geographically, the company operates in Europe, North America and Other regions.
53GF Score

Get the complete analysis for HAM:PI3

Cash Payments is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€47.32
Price
€388.86
GF Value